Restoring invisible and abandoned trials: A call for people to publish the findings

BMJ (Online)

Volumn 346, Issue 7913, 2013, Pages

  Doshi, Peter ^a   Dickersin, Kay ^b,c   Healy, David ^d   Vedula, S Swaroop ^e   Jefferson, Tom ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c US Center   (United States)

^d BANGOR UNIVERSITY   (United Kingdom)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Acute Respiratory Infections Group   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; GABAPENTIN; OSELTAMIVIR; PAROXETINE; QUETIAPINE;

ARTICLE; DRUG MANUFACTURE; HEALTH CARE ACCESS; HUMAN; LAW SUIT; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL RECORD; MEDICAL RESEARCH; POLICY; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLICATION; PUBLISHING;

EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879364075     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f2865     Document Type: Article

References (128)

1. Song F, Parekh S, Hooper L., Loke YK, Ryder J, Sutton AJ, et al Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010;14(8):1-193.
2. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the food and drug administration: review of publication and presentation. Plos Med 2008;5:e217.
3. Doshi P, Jones M, Jefferson T. Rethinking credible evidence synthesis. BMJ 2012;344:d7898.
4. Chan A-W, Hróbjartsson A, Haahr M.T., Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65. (Pubitemid 38669189)
5. Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials 2011;12:249.
6. Turner EH, Matthews AM, Linardatos E, Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
7. Dickersin K, Min YI Publication bias: the problem that won't go away. Ann N Y Acad Sci 1993;703:135-46; discussion 146-8
8. Hopewell S, Loudon K, Clarke M.J., Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 2009;1:MR000006.
9. Melander H. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171-3. (Pubitemid 36649049)
10. McGauran N, Wieseler B, Kreis J., Schuler Y-B, Kolsch H, Kaiser T. Reporting bias in medical research - a narrative review. Trials 2010;11:37.
11. Sismondo S, Doucet M. Publication ethics and the ghost management of medical publication. Bioethics 2009;24:273-83.
12. Vedula SS, Bero L, Scherer R.W., Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009;361:1963-71.
13. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, et al Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012;1:CD008965.
14. Vedula SS, Li T, Dickersin K. Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin. PLoS Med 2013;10:e1001378.
15. Chan A-W. Bias, spin, and misreporting: time for full access to trial protocols and results. Plos Med 2008;5:e230.
16. Califf RM, Zarin DA, Kramer J.M., Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 2012;307:1838-47.
17. Prayle AP, Hurley MN, Smyth AR Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ 2012;344:d7373.
18. Law MR, Kawasumi Y, Morgan SG Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. Health Affairs 2011;30:2338-45.
19. Zarin DA, Tse T, Williams R.J., Califf RM, Ide NC The ClinicalTrials.gov results database - update and key issues. N Engl J Med 2011;364:852-60.
20. European Medicines Agency. European Medicines Agency policy on access to documents (related to medicinal products for human and veterinary use. 2010. www.ema.europa.eu/docs/en-GB/document-library/Other/2010/11/WC500099473.pdf.
21. European Medicines Agency. Output of the European Medicines Agency policy on access to documents related to medicinal products for human and veterinary use. 2010 www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and- procedural-guideline/2010/11/WC500099472.pdf.
22. HMA/EMA Working Group on Transparency. HMA/EMA guidance document on the identification of commercially confidential information and personal data within the structure of the marketing authorisation (MA) application - release of information after the granting of a marketing authorisation. 2012 www.ema.europa.eu/docs/en-GB/document-library/Other/2012/03/WC500124536.pdf.
23. Doshi P, Jefferson T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. JAMA Intern Med 2013;173:380-2.
24. Jureidini JN, McHenry LB, Mansfield PR Clinical trials and drug promotion: Selective reporting of study 329. Int J Risk Safety Med 2008;20:73-81. (Pubitemid 351526054)
25. Newman M. The rules of retraction. BMJ 2010;341:c6985.
26. Boulton G, Rawlins M, Vallance P., Walport M. Science as a public enterprise: the case for open data. Lancet 2011;377:1633-5.
27. Fromer M. Public access to research data: a right to know or off limits? Oncology Times 2001;23:52-4.
28. Chan A-W, Tetzlaff J.M., Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerič K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200-7.
29. Chan A-W, Tetzlaff J.M., Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.
30. Department of Energy. Comprehensive epidemiologic data resource. 2012 www.orau.gov/cedr/.
31. National Heart Lung and Blood Institute. Women's Health Initiative. 2011. www.nhlbi.nih.gov/whi/references.htm.
32. Food and Drug Administration. Food and Drug Administration Amendments Act of 2007.
33. Slade J, Bero LA, Hanauer P, Barnes D.E., Glantz SA Nicotine and Addiction. The Brown and Williamson documents. JAMA 1995;274:225-33.
34. Hersch J, Libert O, Rogg-Effront C. Final report on project hippo I. 1962. http://legacy.library.ucsf.edu/tid/buc72d00/pdf.
35. Pendleton C, Olivi A, Brem H., Quiñones-Hinojosa A. Harvey Cushing's early treatment of meningiomas: the untold story. World Neurosurgery 2011 Nov http://linkinghub.elsevier.com/retrieve/pii/S1878875011010011.
36. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012;82:235-41.
37. Besarab A, Bolton WK, Browne J.K., Egrie JC, Nissenson AR, Okamoto DM, et al The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90. (Pubitemid 28385655)
38. Doshi P, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open 2013;3:e002496.
39. European Medicines Agency. Note for guidance on the inclusion of appendices to clinical study reports in marketing authorisation applications. 2004. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003638.pdf.
40. Glickman SW, McHutchison JG, Peterson E.D., Cairns CB, Harrington RA, Califf RM, et al Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360:816-23.
41. Mirowski P, Van Horn R. The contract research organization and the commercialization of scientific research. Soc Stud Sci 2005;35:503-48. (Pubitemid 41186379)
42. Mello MM, Clarridge BR, Studdert DM Academic medical centers' standards for clinical-trial agreements with industry. N Engl J Med 2005;352:2202-10. (Pubitemid 40727087)
43. Healy D. Pharmageddon. 1st ed. University of California Press, 2012.
44. Blumsohn A. Authorship, ghost-science, access to data and control of the pharmaceutical scientific literature: who stands behind the word? AAAS Professional Ethics Report 2006;19:1-4.
45. Korn D, Ehringhaus S. Principles for strengthening the integrity of clinical research. PLoS Clin Trials 2006. www.ncbi.nlm.nih.gov/pmc/articles/ PMC1488888/.
46. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Structure and content of clinical study reports: E3. 1995 www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E3/E3-Guideline.pdf.
47. Hendrick R. Ghosts in the machine. BMJ 2011;343:d7860.
48. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med 2012;9:e1001201.
49. Unlu M. It is time: why the FDA should start disclosing drug trial data. Mich Telecomm Tech L Rev 2010;16:511-45.
50. Hoffmann-La Roche. Roche launches new process for accessing clinical trial data Press release, 26 Feb 2013. www.roche.com/media/media-releases/med- cor-2013-02-26.htm.
51. Glaxo Smith Kline. GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges. Press release, 11 Oct 2012. www.gsk.com/media/press-releases/2012/GSK-announces-further-initiatives- to-tackle-global-health-challenges.html.
52. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
53. Hrynaszkiewicz I, Norton ML, Vickers A.J., Altman DG Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ 2010;340:c181.
54. Laine C, Goodman SN, Griswold M.E., Sox HC Reproducible research: moving toward research the public can really trust. Ann Intern Med 2007;146:450-3. (Pubitemid 351650578)
55. Groves T. BMJ policy on data sharing. BMJ 2010 Jan 28;340:c564.
56. Hanson B, Sugden A, Alberts B. Making data maximally available. Science 2011;331:649.
57. Bauchner H, Fontanarosa PB Restoring confidence in the pharmaceutical industry. JAMA 2013;309:607-9.
58. Eichler H-G, Abadie E., Breckenridge A, Leufkens H, Rasi G. Open clinical trial data for all? a view from regulators. PLoS Med 2012;9:e1001202.
59. Rennie D, Yank V, Emanuel L. When authorship fails. A proposal to make contributors accountable. JAMA 1997;278:579-85. (Pubitemid 27353608)
60. Smith R. Authorship is dying: long live contributorship. BMJ 1997;315:696.
61. Horton R. The signature of responsibility. Lancet 1997;350:5-6. (Pubitemid 27279760)
62. Cohen D. Complications: tracking down the data on oseltamivir. BMJ 2009;339:b5387.
63. Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold "HRT,". PLoS Med 2010;7:e1000335.
64. Mansi BA, Clark J, David F.S., Gesell TM, Glasser S, Gonzalez J, et al Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspective. Mayo Clin Proc 2012;87:424-9.
65. University of California. Legacy tobacco documents library. 2007. http://legacy.library.ucsf.edu/.
66. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter T.A., Weisler RH, et al A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-60. (Pubitemid 40905587)
67. Newcomer JW, Ratner RE, Eriksson J.W., Emsley R., Meulien D, Miller F, et al A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 2009;70:487-99.
68. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
69. Yusuf S, Zhao F, Mehta S.R., Chrolavicius S., Tognoni G, Fox KK Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
70. Sabatine MS, McCabe CH, Gibson C.M., Cannon CP Design and rationale of clopidogrel as adjunctive reperfusion therapy-thrombolysis in myocardial infarction (CLARITY-TIMI) 28 trial. Am Heart J 2005;149:227-33. (Pubitemid 40348527)
71. Sabatine MS, Cannon CP, Gibson C.M., López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89. (Pubitemid 40397259)
72. Chen ZM, Jiang LX, Chen Y.P., Xie JX, Pan HC, Peto R, et al Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.
73. Li JS, Yow E, Berezny K.Y., Bokesch PM, Takahashi M, Graham TP Jr, et al Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. Circulation 2008;117:553-9.
74. Keck PE, Orsulak PJ, Cutler A.J., Sanchez R., Torbeyns A, Marcus RN, et al Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009;112:36-49.
75. Rümke H.C., Bayas J-M, De Juanes J-R, Caso C, Richardus JH, Campins M, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008;26:2378-88.
76. Keller MB, Ryan ND, Strober M, Klein R.G., Kutcher SP, Birmaher B, et al Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-72. (Pubitemid 32595260)
77. Berard R, Fong R, Carpenter D.J., Thomason C., Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2006;16:59-75.
78. Geller DA, Biederman J, Stewart S.E., Mullin B., Farrell C, Wagner KD, et al Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J Child Adolesc Psychopharmacol 2003;13(suppl. 1):S19-29. (Pubitemid 36886091)
79. Braconnier A, Le Coent R, Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 2003;42:22-9. (Pubitemid 39610610)
80. Emslie GJ, Wagner KD, Kutcher S, Krulewicz S., Fong R, Carpenter DJ, et al Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2006;45:709-19. (Pubitemid 43833104)
81. Geller DA, Wagner KD, Emslie G, Murphy T., Carpenter DJ, Wetherhold E, et al Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004;43:1387-96. (Pubitemid 39411039)
82. Findling RL, Nucci G, Piergies A.A., Gomeni R., Bartolic EI, Fong R, et al Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacol 2006;31:1274-85. (Pubitemid 43971843)
83. Wagner KD, Berard R, Stein M.B., Wetherhold E., Carpenter DJ, Perera P, et al A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004;61:1153-62. (Pubitemid 39463417)
84. Fong R, Carpenter D, Lipschitz A., Krulewicz S, Machin A, Wilkinson C. Long-term safety and tolerability of paroxetine. J Child Adolesc Psychopharmacol 2005;15:856.
85. Matsumoto K, Ogawa N, Nerome K., Numazaki Y, Kawakami Y, Shirato K., et al Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. Antivir Ther 1999;4:61-8. (Pubitemid 29355843)
86. Murphy KR, Eivindson A, Pauksens K., Stein WJ, Tellier G, Watts R, et al Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Investig 2000;20:337-49.
87. Hedrick JA, Barzilai A, Behre U., Henderson FW, Hammond J, Reilly L, et al Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000;19:410-7. (Pubitemid 30307990)
88. Hayden FG, Gubareva LV, Monto A.S., Klein TC, Elliot MJ, Hammond JM, et al Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000;343:1282-9.
89. Puhakka T, Lehti H, Vainionpää R, Jormanainen V, Pulkkinen M, Sharp S, et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis 2003;35:52-8. (Pubitemid 36336368)
90. Monto AS, Pichichero ME, Blanckenberg S.J., Ruuskanen O., Cooper C, Fleming DM, et al Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002;186:1582-8. (Pubitemid 35379634)
91. LaForce C, Man CY, Henderson F.W., McElhaney JE, Hampel FC Jr, Bettis R, et al Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2007;29:1579-90; discussion 1577-8 (Pubitemid 47500131)
92. Hayden FG, Osterhaus ADME, Treanor JJ, Fleming D.M., Aoki FY, Nicholson KG, et al Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997;337:874-80. (Pubitemid 27408569)
93. Peng AW, Hussey EK, Moore KH A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. J Clin Pharmacol 2000;40:242-9.
94. Schilling M, Povinelli L, Krause P., Gravenstein M, Ambrozaitis A, Jones H.H., et al Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998;16:1771-4. (Pubitemid 28545109)
95. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999;44(suppl. 2):23-9. (Pubitemid 29531321)
96. Gravenstein S, Drinka P, Osterweil D., Schilling M, Krause P, Elliott M., et al Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc 2005;6:359-66. (Pubitemid 41755354)
97. Ambrozaitis A, Gravenstein S, van Essen GA, Rubinstein E, Balciuniene L, Stikleryte A., et al Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. J Am Med Dir Assoc 2005;6:367-74. (Pubitemid 41755355)
98. Monto AS, Robinson DP, Herlocher M.L., Hinson JM, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282:31-5. (Pubitemid 29318929)
99. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T., et al Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis 1999;180:254-61. (Pubitemid 30256303)
100. Kaiser L, Henry D, Flack N.P., Keene O., Hayden FG Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis 2000;30:587-9. (Pubitemid 30205311)
101. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352:1877-81.
102. Mäkelä MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000;40:42-8. (Pubitemid 30157772)
103. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T., Durando P, Montomoli E, et al MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009;4:e4384.
104. Vesikari T, Karvonen A, Tilman S., Borkowski A, Montomoli E, Banzhoff A., et al Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010;126:e762-70.
105. Backonja M, Beydoun A, Edwards K.R., Schwartz SL, Fonseca V, Hes M, et al Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6. (Pubitemid 28544423)
106. Pande AC, Crockatt JG, Janney C.A., Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000;2:249-55.
107. Mathew NT, Rapoport A, Saper J., Magnus L, Klapper J, Ramadan N., et al Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-28. (Pubitemid 32209899)
108. Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002;99:557-66. (Pubitemid 35284287)
109. Gordh TE, Stubhaug A, Jensen T.S., Arnèr S, Biber B., Boivie J, et al Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain 2008;138:255-66.
110. Gómez-Pérez FJ, Perez-Monteverde A, Nascimento O, Aschner P, Tagle M, Fichtner K, et al. Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response. Br J Diabetes Vasc Dis 2004;4:173-8. (Pubitemid 38967711)
111. Caraceni A, Zecca E, Bonezzi C., Arcuri E, Yaya Tur R, Maltoni M, et al Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004;22:2909-17. (Pubitemid 41079911)
112. Vieta E, Manuel Goikolea J, Martínez-Arán A, Comes M, Verger K, Masramon X, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006;67:473-7.
113. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000;20:28-34. (Pubitemid 30056350)
114. Massana J, Möller HJ, Burrows G.D., Montenegro RM Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80. (Pubitemid 29149865)
115. Ferguson JM, Wesnes KA, Schwartz GE Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003;18:9-14. (Pubitemid 36127055)
116. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol 2006;20:91-6.
117. Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol 2006;26:121-7. (Pubitemid 43740334)
118. Hayden FG, Atmar RL, Schilling M, Johnson C., Poretz D, Paar D, et al Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336-43. (Pubitemid 29503572)
119. Nicholson KG, Aoki FY, Osterhaus A.D., Trottier S., Carewicz O, Mercier CH, et al Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000;355:1845-50. (Pubitemid 30311875)
120. Treanor JJ, Hayden FG, Vrooman P.S., Barbarash R., Bettis R, Riff D, et al Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000;283:1016-24. (Pubitemid 30112215)
121. Hayden FG, Jennings L, Robson R., Schiff G, Jackson H, Rana B., et al Oral oseltamivir in human experimental influenza B infection. Antivir Ther (Lond) 2000;5:205-13.
122. Welliver R, Monto AS, Carewicz O, Schatteman E., Hassman M, Hedrick J, et al Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:748-54. (Pubitemid 32167233)
123. Peters PH J.r., Gravenstein S, Norwood P., De Bock V, Van Couter A, Gibbens M, et al Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001;49:1025-31. (Pubitemid 32801138)
124. Whitley RJ, Hayden FG, Reisinger K.S., Young N., Dutkowski R, Ipe D, et al Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127-33. (Pubitemid 32151932)
125. Johnston SL, Ferrero F, Garcia M.L., Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 2005;24:225-32. (Pubitemid 40365856)
126. Dutkowski R, Smith JR, Davies BE Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicrob Agents 2010;35:461-7.
127. Hayden FG, Belshe R, Villanueva C., Lanno R, Hughes C, Small I., et al Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004;189:440-9. (Pubitemid 38210580)
128. Aronoff S, Rosenblatt S, Braithwaite S., Egan JW, Mathisen AL, Schneider RL Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000;23:1605-11.